Multifunctional aptamer-nucleic acid nanostructures for tumor-targeted killing
View Patent ↗The present invention provides compositions comprising a ligand-nucleic acid nanostructure that promote tumor cell-specific killing and methods of using the compositions. Specially, the invention provides aptamer-nucleic acid nanostructures for treating tumors in a mammal. The methods of making the compositions are also provided.
1. A composition comprising a first ligand that is specific for binding to a tumor cell, and a second ligand that is specific for binding to a death receptor on the tumor cell, wherein the first and second ligands are bound to a nucleic acid nanostructure, wherein the first ligand is a first aptamer and the second ligand is a second aptamer, and wherein the nucleic acid nanostructure comprises a nucleic acid tile.
2. The composition of claim 1 , wherein the first aptamer is specific for binding to a tumor antigen on the surface of the tumor cell.
3. The composition of claim 2 , wherein the tumor antigen is CD20.
4. The composition of claim 1 , wherein the death receptor is TRAIL Receptor 1 (TRAIL-R1), TRAIL Receptor 2 (TRAIL-R2) or tumor necrosis factor receptor (TNFR).
5. The composition of claim 1 , wherein the distance between the first aptamer and the second aptamer on the nucleic acid nano structure is about 10 nm to about 15 nm.
6. The composition of claim 1 , wherein the first aptamer comprises a plurality of first aptamers, and the second aptamer comprises a plurality of second aptamers.
7. The composition of claim 6 wherein the plurality of first aptamers is present on the nucleic acid nanostructure at a density of 5-10 aptamers per nucleic acid nanostructure, and the plurality of second aptamers is present on the nucleic acid nanostructure at a density of 5-10 aptamers per nucleic acid nanostructure.
8. The composition of claim 7 wherein the distance between each aptamer of the plurality of first aptamers and the distance between each aptamer of the plurality of second aptamers on the nucleic acid nanostructure is about 5 nm to about 8 nm.
9. The composition of claim 8 , wherein the ratio of first aptamers to second aptamers on the nucleic acid nanostructure is 1:1.
10. The composition of claim 1 , wherein the first aptamer comprises a dimer, trimer, tetramer, or pentamer of an aptamer that is specific for a tumor cell.
11. The composition of claim 10 , wherein the second aptamers comprises a dimer, trimer, tetramer, or pentamer of an aptamer that is specific for binding to the death receptor.
12. The composition of claim 11 , wherein the first aptamer comprises a plurality of first aptamers, and the second aptamer comprises a plurality of second aptamers.
13. The composition of claim 12 wherein the plurality of first aptamers is present on the nucleic acid nanostructure at a density of 5-10 aptamers per nucleic acid nanostructure, and the plurality of second aptamers is present on the nucleic acid nanostructure at a density of 5-10 aptamers per nucleic acid nanostructure.
14. The composition of claim 13 wherein the distance between each aptamer of the plurality of first aptamers and the distance between each aptamer of the plurality of second aptamers on the nucleic acid nanostructure is about 10 nm to about 15 nm.
15. The composition of claim 14 , wherein the ratio of first aptamers to second aptamers on the nucleic acid nanostructure is 1:1.
16. The composition of claim 6 , wherein the first aptamer comprises a plurality of first aptamers that are specific for binding to at least two different tumor antigens on the surface of the tumor cell.
17. The composition of claim 6 , wherein the second aptamer comprises a plurality of second aptamers that are specific for binding to at least two different death receptors.
18. The composition of claim 1 , further comprising an apoptosis inducer that is bound to the nucleic acid nanostructure.
19. The composition of claim 18 , wherein the apoptosis inducer is an NF-KB inhibitor.
20. The composition of claim 19 wherein the NF-KB inhibitor is a decoy oligonucleotide.
21. The composition of claim 1 , wherein the nucleic acid nanostructure is between about 10 nm and about 2000 nm in length.
22. The composition of claim 1 , wherein the nucleic acid nanostructure comprises a plurality of nucleic acid tiles.
23. The composition of claim 22 , wherein the plurality of nucleic acid tiles forms a nucleic acid tiling array.
24. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.